Torrent Pharma delivered a textbook quarter — revenues up 18 per cent year-on-year to Rs 33 billion, profits climbing 26 per cent to Rs 6.4 billion, and EBITDA margins nudging up 40 basis points to 32.9 per cent. In the ordinary course of business, that would have been the headline.Continue Reading

Pharma major’s 284 bps EBITDA margin gain and Unichem turnaround strategy draw bullish analyst calls  IPCA Laboratories has emerged as a growth story in India’s pharmaceutical sector with two leading brokerages issuing buy recommendations following the company’s third-quarter performance that showcased margin expansion even as revenue growth remained modest. TheContinue Reading

With Nifty IT down 15% in a month and FCF yields at crisis levels, analysts ask: Is this a Kodak moment or a generational buying opportunity? The question haunting Dalal Street’s technology corner isn’t whether AI will disrupt Indian IT services. It’s whether the disruption has already been priced inContinue Reading

A 50% revenue surge and 400% profit jump have made analysts sit up and take notice When a mid-cap jewellery stock delivers revenue growth of 50% and profit growth north of 400% in a single quarter, you’d expect analysts to be tripping over themselves. Senco Gold’s Q3FY26 results has drivenContinue Reading